|
US3773919A
(en)
|
1969-10-23 |
1973-11-20 |
Du Pont |
Polylactide-drug mixtures
|
|
US4263428A
(en)
|
1978-03-24 |
1981-04-21 |
The Regents Of The University Of California |
Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
|
|
DE3169595D1
(en)
|
1980-11-10 |
1985-05-02 |
Gersonde Klaus |
Method of preparing lipid vesicles by ultrasonic treatment, the use of this method and apparatus for its application
|
|
US4485045A
(en)
|
1981-07-06 |
1984-11-27 |
Research Corporation |
Synthetic phosphatidyl cholines useful in forming liposomes
|
|
DE3374837D1
(en)
|
1982-02-17 |
1988-01-21 |
Ciba Geigy Ag |
Lipids in the aqueous phase
|
|
DE3218121A1
(de)
|
1982-05-14 |
1983-11-17 |
Leskovar, Peter, Dr.-Ing., 8000 München |
Arzneimittel zur tumorbehandlung
|
|
EP0102324A3
(de)
|
1982-07-29 |
1984-11-07 |
Ciba-Geigy Ag |
Lipide und Tenside in wässriger Phase
|
|
US4544545A
(en)
|
1983-06-20 |
1985-10-01 |
Trustees University Of Massachusetts |
Liposomes containing modified cholesterol for organ targeting
|
|
HUT35524A
(en)
|
1983-08-02 |
1985-07-29 |
Hoechst Ag |
Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
|
|
DE3483949D1
(de)
|
1983-09-26 |
1991-02-21 |
Udo Dr Med Ehrenfeld |
Mittel und erzeugnis fuer die diagnose und therapie von tumoren sowie zur behandlung von schwaechen der zelligen und humoralen immunabwehr.
|
|
DE3474511D1
(en)
|
1983-11-01 |
1988-11-17 |
Terumo Corp |
Pharmaceutical composition containing urokinase
|
|
US6051256A
(en)
|
1994-03-07 |
2000-04-18 |
Inhale Therapeutic Systems |
Dispersible macromolecule compositions and methods for their preparation and use
|
|
AU756693B2
(en)
|
1997-09-29 |
2003-01-23 |
Novartis Ag |
Stabilized bioactive preparations and methods of use
|
|
EP1034826A1
(en)
|
1999-03-05 |
2000-09-13 |
Reuter Chemische Apparatebau |
Co-crystallization process
|
|
JP2001089452A
(ja)
|
1999-09-22 |
2001-04-03 |
Sankyo Co Ltd |
ピリミジン誘導体
|
|
PT1280520E
(pt)
|
2000-05-10 |
2014-12-16 |
Novartis Ag |
Pós à base de fosfolípidos para administração de fármacos
|
|
WO2002022605A1
(en)
|
2000-09-15 |
2002-03-21 |
Vertex Pharmaceuticals Incorporated |
Pyrazole compounds useful as protein kinase inhibitors
|
|
PT1458360E
(pt)
|
2001-12-19 |
2011-07-13 |
Novartis Ag |
Derivados de indole como agonistas do recetor s1p1
|
|
US20070265289A1
(en)
|
2004-04-15 |
2007-11-15 |
Yoshinori Okamoto |
2-Aminopyrimidine Derivative
|
|
PL2044056T3
(pl)
|
2006-07-14 |
2013-01-31 |
Novartis Ag |
Pochodne pirymidyny jako inhibitory ALK-5
|
|
JP4616237B2
(ja)
|
2006-11-07 |
2011-01-19 |
日本電信電話株式会社 |
シリコン化合物薄膜の形成方法
|
|
AR068877A1
(es)
|
2007-10-17 |
2009-12-09 |
Novartis Ag |
Derivados heterociclicos de imidazol
|
|
WO2013148114A1
(en)
|
2012-03-30 |
2013-10-03 |
University Of Florida Research Foundation, Inc. |
P300/cbp inhibitors and methods of use
|
|
TW201414737A
(zh)
|
2012-07-13 |
2014-04-16 |
必治妥美雅史谷比公司 |
作爲激酶抑制劑之咪唑并三□甲腈
|
|
JP6523251B2
(ja)
|
2013-05-01 |
2019-05-29 |
エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ |
Ｃ−結合ヘテロシクロアルキル置換ピリミジン類及びそれらの用途
|
|
MX2016004570A
(es)
|
2013-10-11 |
2016-09-08 |
Genentech Inc |
Uso de inhibidores del bromodominio de cbp/ep300 para la inmunoterapia del cáncer.
|
|
PL3089971T3
(pl)
|
2014-01-01 |
2021-01-25 |
Medivation Technologies Llc |
Związki i sposoby ich zastosowania
|
|
EA201790627A1
(ru)
|
2014-09-17 |
2017-09-29 |
Айронвуд Фармасьютикалз, Инк. |
СТИМУЛЯТОРЫ рГЦ
|
|
WO2016123054A2
(en)
|
2015-01-26 |
2016-08-04 |
The University Of North Carolina At Chapel Hill |
Kinase drug combinations and methods of use thereof
|
|
CN106146508A
(zh)
|
2015-03-19 |
2016-11-23 |
浙江导明医药科技有限公司 |
优化的联合用药及其治疗癌症和自身免疫疾病的用途
|
|
AU2016270373A1
(en)
|
2015-06-05 |
2018-01-04 |
Vertex Pharmaceuticals Incorporated |
Triazoles for the treatment of demyelinating diseases
|
|
KR20180095094A
(ko)
*
|
2016-01-08 |
2018-08-24 |
셀진 코포레이션 |
암을 치료하기 위한 방법 및 치료요법에 대한 임상 감수성의 예측변수로서 바이오마커의 용도
|
|
CN110621316B
(zh)
|
2017-04-21 |
2024-01-26 |
Epizyme股份有限公司 |
用ehmt2抑制剂进行的组合疗法
|
|
IT201700047189A1
(it)
*
|
2017-05-02 |
2018-11-02 |
Fondazione St Italiano Tecnologia |
Composti e composizioni per il trattamento di cancro, disordini della retina e cardiomiopatie
|
|
AU2018273356B2
(en)
|
2017-05-22 |
2021-09-16 |
Amgen Inc. |
KRAS G12C inhibitors and methods of using the same
|
|
MY205552A
(en)
|
2017-05-30 |
2024-10-25 |
Deciphera Pharmaceuticals Inc |
Use of 1-[4-bromo-5-[1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl]-2-fluorophenyl ]-3-phenylurea and analogs for the treatment of cancers associated with genetic abnormalities in platelet derived growth factor receptor alpha
|
|
KR20200036880A
(ko)
|
2017-08-03 |
2020-04-07 |
노파르티스 아게 |
3세대 EGFR 타이로신 키나아제 억제제 및 Raf 억제제의 치료적 조합물
|
|
US20200155566A1
(en)
|
2017-08-03 |
2020-05-21 |
Novartis Ag |
Therapeutic combination of a third generation egfr tyrosine kinase inhibitor and a cyclin d kinase inhibitor
|
|
EP3675861A4
(en)
|
2017-09-01 |
2021-01-06 |
Kadmon Corporation, LLC |
ALPHA SUPERWINDING PROTEIN KINASE INHIBITORS ("COILED-COIL") ASSOCIATED WITH RHO
|
|
LT3710439T
(lt)
|
2017-11-15 |
2023-05-10 |
Mirati Therapeutics, Inc. |
Kras g12c inhibitoriai
|
|
KR102940906B1
(ko)
|
2017-11-20 |
2026-03-18 |
톨레모 테라퓨틱스 아게 |
진단 방법
|
|
US12290521B2
(en)
|
2018-07-25 |
2025-05-06 |
Mayo Foundation For Medical Education And Research |
Methods and materials for identifying and treating BET inhibitor-resistant cancers
|
|
WO2020035065A1
(zh)
|
2018-08-17 |
2020-02-20 |
南京明德新药研发有限公司 |
作为ret抑制剂的吡唑衍生物
|
|
WO2020045941A1
(ko)
|
2018-08-27 |
2020-03-05 |
주식회사 대웅제약 |
신규한 헤테로사이클릭아민 유도체 및 이를 포함하는 약학 조성물
|
|
EP3849537B1
(en)
|
2018-09-10 |
2024-10-23 |
Mirati Therapeutics, Inc. |
Combination therapies
|
|
ES3017461T3
(en)
|
2018-09-10 |
2025-05-13 |
Mirati Therapeutics Inc |
Combination of dasatinib and adagrasib for use in the treatment of non-small cell lung cancer
|
|
EA202190749A1
(ru)
|
2018-09-10 |
2021-07-09 |
Мирати Терапьютикс, Инк. |
Способы комбинированной терапии
|
|
EP3849535A4
(en)
|
2018-09-10 |
2022-06-29 |
Mirati Therapeutics, Inc. |
Combination therapies
|
|
MX2021002804A
(es)
|
2018-12-05 |
2021-07-15 |
Mirati Therapeutics Inc |
Terapias de combinacion.
|
|
WO2020127200A1
(en)
|
2018-12-17 |
2020-06-25 |
Tolremo Therapeutics Ag |
Heterocyclic derivatives, pharmaceutical compositions and their use in the treatment, amelioration or prevention of cancer
|
|
EP4041399A1
(en)
*
|
2019-10-02 |
2022-08-17 |
Tolremo Therapeutics AG |
Heterocyclic derivatives, pharmaceutical compositions and their use in the treatment or amelioration of cancer
|
|
AU2020377925A1
(en)
|
2019-11-04 |
2022-05-05 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
CN115397818A
(zh)
|
2020-03-27 |
2022-11-25 |
东亚St株式会社 |
氨基嘧啶衍生物及其作为芳烃受体调节剂的应用
|
|
KR20230028798A
(ko)
|
2020-06-25 |
2023-03-02 |
톨레모 테라퓨틱스 아게 |
암 치료를 위한 CBP/p300 브로모도메인 억제제 및 KRAS 억제제의 조합물
|
|
BR112022025911A2
(pt)
|
2020-06-25 |
2023-01-10 |
Tolremo Therapeutics Ag |
Combinação de um inibidor de bromodomínio de cbp/p300 e um inibidor de egfr para uso no tratamento de um cpcnp com egfr mutante
|
|
WO2021260110A1
(en)
|
2020-06-25 |
2021-12-30 |
Tolremo Therapeutics Ag |
Heterocyclic derivatives, pharmaceutical compositions and their use in the treatment, amelioration or prevention of fibrotic disease
|